These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 31849930)

  • 1. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
    Nunes NS; Kanakry CG
    Front Immunol; 2019; 10():2668. PubMed ID: 31849930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.
    Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Gress RE; Kanakry CG
    J Clin Invest; 2019 Mar; 129(6):2357-2373. PubMed ID: 30913039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
    Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
    Front Immunol; 2022; 13():796349. PubMed ID: 35242129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized Timing of Post-Transplantation Cyclophosphamide in MHC-Haploidentical Murine Hematopoietic Cell Transplantation.
    Wachsmuth LP; Patterson MT; Eckhaus MA; Venzon DJ; Kanakry CG
    Biol Blood Marrow Transplant; 2020 Feb; 26(2):230-241. PubMed ID: 31586477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects.
    Patterson MT; Khan SM; Nunes NS; Fletcher RE; Bian J; Hadjis AD; Eckhaus MA; Mendu SK; de Paula Pohl A; Venzon DJ; Choo-Wosoba H; Ishii K; Qin H; Fry TJ; Cam M; Kanakry CG
    Blood; 2023 Feb; 141(6):659-672. PubMed ID: 36201744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
    Nakamae H
    Int J Hematol; 2022 Oct; 116(4):465-481. PubMed ID: 35930118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
    Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
    Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current state of graft-versus-host disease prophylaxis with PTCy for allogeneic hematopoietic stem cell transplantation].
    Nakamae H
    Rinsho Ketsueki; 2024; 65(5):391-400. PubMed ID: 38825519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
    Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
    Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Graft-versus-Host Disease on Post-Transplantation Outcomes following Single Cord Blood Transplantation Compared with Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Adult Acute Myeloid Leukemia.
    Konuma T; Matsuda K; Shimomura Y; Tanoue S; Sugita J; Inamoto Y; Hirayama M; Ara T; Nakamae H; Ota S; Maruyama Y; Eto T; Uchida N; Tanaka M; Ishiwata K; Koi S; Takahashi S; Ozawa Y; Onizuka M; Kanda Y; Kimura T; Ichinohe T; Atsuta Y; Kanda J; Yanada M
    Transplant Cell Ther; 2023 Jun; 29(6):365.e1-365.e11. PubMed ID: 36889507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
    Mohty R; Al Kadhimi Z; Kharfan-Dabaja M
    Hematology; 2024 Dec; 29(1):2326384. PubMed ID: 38597828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.
    Nakamae H
    Front Immunol; 2024; 15():1403936. PubMed ID: 38903503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sigle Agent of Posttransplant Cyclophosphamide Without Calcineurin Inhibitor Controls Severity of Experimental Chronic GVHD.
    Saeki K; Fujiwara H; Seike K; Kuroi T; Nishimori H; Tanaka T; Matsuoka KI; Fujii N; Maeda Y
    Acta Med Okayama; 2024 Apr; 78(2):123-134. PubMed ID: 38688830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
    Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
    Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform.
    Mayumi H
    Front Immunol; 2021; 12():744430. PubMed ID: 34659242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification.
    Li Y; Wang N; Zhang X; Cao Y; Zhang L; Liu A; Zhang Y
    Blood Rev; 2023 Nov; 62():101078. PubMed ID: 37031067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.